About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Assessing Cosopt Switch Patients

NCT00273442·5 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pharmaceutical Research Network

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
visual acuity should be 20/200 or better in each eye

You may not be if

contraindications to study drugs
anticipated change in systemic hypotensive therapy during the trial
use of any corticosteroids by any route in the three months immediately prior to Visit 2

The record

StatusCompleted

PhasePhase 4

Taking part60

StartedNov 2005

UpdatedNov 19, 2008

Conditions

Ocular Hypertension Open-Angle Glaucoma Exfoliation Syndrome Glaucoma, Pigmentary

Where5

Little Rock Eye Clinic
Little Rock, Arkansas, United States
Omni Eye Services
Atlanta, Georgia, United States
Midwest Eye Center
Bourbonnais, Illinois, United States

Clareo Health | Assessing Cosopt Switch Patients